Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …

We review the progress achieved during the recent five years in immunochemical
biosensors (immunosensors) combined with nanoparticles for enhanced sensitivity. The …

Safety and efficacy constitute the major criteria governing regulatory approval of any new
drug. The best method to maximize safety and efficacy is to deliver a proven therapeutic …

Antibody therapies have become an important class of therapeutics in recent years as they
have exhibited outstanding efficacy and safety in the treatment of several major diseases …

Recent clinical trials have demonstrated the ability to durably control cancer in some
patients by manipulating T lymphocytes. These immunotherapies are revolutionizing cancer …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Bacterial pathogens are important targets for detection and identification in medicine, food
safety, public health, and security. Bacterial infection is a common cause of morbidity and …

As medicine progresses into a new era of personalised therapy, the use of monoclonal
antibodies to treat a wide range of diseases lies at the heart of this new forefront. Since the …

With the current biotherapeutic market dominated by antibody molecules, bispecific
antibodies represent a key component of the next-generation of antibody therapy. Bispecific …